CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Corvus Pharmaceuticals, Inc. - CRVS CFD

1.4447
2.85%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0306
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Corvus Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.4047
Open* 1.4147
1-Year Change* 93.79%
Day's Range* 1.3947 - 1.4947
52 wk Range 0.61-4.19
Average Volume (10 days) 682.61K
Average Volume (3 months) 12.34M
Market Cap 80.30M
P/E Ratio -100.00K
Shares Outstanding 48.97M
Revenue N/A
EPS -0.84
Dividend (Yield %) N/A
Beta 0.99
Next Earnings Date Nov 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 29, 2023 1.4447 0.0500 3.59% 1.3947 1.4947 1.3947
Sep 28, 2023 1.4047 0.0000 0.00% 1.4047 1.4447 1.3947
Sep 27, 2023 1.4447 0.0300 2.12% 1.4147 1.4747 1.3947
Sep 26, 2023 1.4547 0.0900 6.59% 1.3647 1.5647 1.3247
Sep 25, 2023 1.4147 -0.0800 -5.35% 1.4947 1.4947 1.3647
Sep 22, 2023 1.5047 0.0100 0.67% 1.4947 1.5247 1.4847
Sep 21, 2023 1.5047 0.0000 0.00% 1.5047 1.5747 1.4947
Sep 20, 2023 1.5147 -0.0100 -0.66% 1.5247 1.5947 1.5047
Sep 19, 2023 1.5547 -0.0100 -0.64% 1.5647 1.5847 1.5247
Sep 18, 2023 1.5547 0.0000 0.00% 1.5547 1.5747 1.5147
Sep 15, 2023 1.5747 0.0100 0.64% 1.5647 1.5847 1.5447
Sep 14, 2023 1.5747 -0.0500 -3.08% 1.6247 1.6447 1.5447
Sep 13, 2023 1.6147 -0.0900 -5.28% 1.7047 1.7647 1.5947
Sep 12, 2023 1.7047 -0.0900 -5.01% 1.7947 1.8147 1.6947
Sep 11, 2023 1.8247 0.0700 3.99% 1.7547 1.9047 1.7047
Sep 8, 2023 1.6813 0.0800 5.00% 1.6013 1.7213 1.6013
Sep 7, 2023 1.5613 -0.5100 -24.62% 2.0713 2.1713 1.4713
Sep 6, 2023 2.0413 -0.0100 -0.49% 2.0513 2.1313 1.9913
Sep 5, 2023 2.0913 0.0400 1.95% 2.0513 2.1213 2.0313
Sep 1, 2023 2.0913 0.0300 1.46% 2.0613 2.1413 2.0113

Corvus Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Wednesday, November 1, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Corvus Pharmaceuticals Inc Earnings Release
Q3 2023 Corvus Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 32.565 38.63 6.301 48.854 49.222
Selling/General/Admin. Expenses, Total 8.097 9.515 11.93 10.879 10.636
Research & Development 24.468 29.115 31.83 37.975 38.586
Operating Income -32.565 -38.63 -6.301 -48.854 -49.222
Interest Income (Expense), Net Non-Operating -9.351 -4.846 0.306 2.182 2.283
Net Income Before Taxes -41.307 -43.241 -5.995 -46.672 -46.939
Net Income After Taxes -41.307 -43.241 -5.995 -46.672 -46.939
Net Income Before Extra. Items -41.307 -43.241 -5.995 -46.672 -46.939
Net Income -41.307 -43.241 -5.995 -46.672 -46.939
Income Available to Common Excl. Extra. Items -41.307 -43.241 -5.995 -46.672 -46.939
Income Available to Common Incl. Extra. Items -41.307 -43.241 -5.995 -46.672 -46.939
Diluted Net Income -41.307 -43.241 -5.995 -46.672 -46.939
Diluted Weighted Average Shares 46.5535 41.8541 29.4789 29.3498 27.51
Diluted EPS Excluding Extraordinary Items -0.8873 -1.03314 -0.20337 -1.5902 -1.70625
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.88777 -1.03314 -1.47407 -1.5902 -1.70625
Unusual Expense (Income) 0 0 -37.459
Other, Net 0.587 0.235
Gain (Loss) on Sale of Assets 0.022
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 5.622 6.574 5.666 12.473 7.013
Selling/General/Admin. Expenses, Total 1.654 1.98 1.586 2.108 2.09
Research & Development 3.968 4.594 4.08 10.365 4.923
Operating Income -5.622 -6.574 -5.666 -12.473 -7.013
Interest Income (Expense), Net Non-Operating -0.881 -1.355 -4.32 -2.505 -1.496
Net Income Before Taxes -6.503 -7.873 -9.816 -14.831 -8.363
Net Income After Taxes -6.503 -7.873 -9.816 -14.831 -8.363
Net Income Before Extra. Items -6.503 -7.873 -9.816 -14.831 -8.363
Net Income -6.503 -7.873 -9.816 -14.831 -8.363
Income Available to Common Excl. Extra. Items -6.503 -7.873 -9.816 -14.831 -8.363
Income Available to Common Incl. Extra. Items -6.503 -7.873 -9.816 -14.831 -8.363
Diluted Net Income -6.503 -7.873 -9.816 -14.831 -8.363
Diluted Weighted Average Shares 47.4974 46.5562 46.5535 46.5535 46.5535
Diluted EPS Excluding Extraordinary Items -0.13691 -0.16911 -0.21085 -0.31858 -0.17964
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.13691 -0.16911 -0.21133 -0.31858 -0.17964
Other, Net 0 0.056 0.148 0.147 0.146
Unusual Expense (Income) 0
Gain (Loss) on Sale of Assets 0.022
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 43.664 71.312 45.336 79.344 115.589
Cash and Short Term Investments 42.303 69.451 44.259 77.982 114.597
Cash & Equivalents 13.159 63.458 16.455 5.154 39.196
Short Term Investments 29.144 5.993 27.804 72.828 75.401
Total Receivables, Net 0.633 0.539 0.086 0.329 0.337
Prepaid Expenses 0.626 1.194 0.585 0.547 0.39
Other Current Assets, Total 0.102 0.128 0.406 0.486 0.265
Total Assets 68.24 109.455 85.529 83.646 118.232
Property/Plant/Equipment, Total - Net 2.57 3.641 2.554 3.789 2.18
Property/Plant/Equipment, Total - Gross 7.116 7.893 6.346 6.949 4.597
Accumulated Depreciation, Total -4.546 -4.252 -3.792 -3.16 -2.417
Other Long Term Assets, Total 0.129 0.236 0.414 0.513 0.463
Total Current Liabilities 10.752 9.692 12.149 10.225 7.027
Accounts Payable 1.976 1.565 3.467 2.448 1.998
Accrued Expenses 8.776 8.127 8.682 7.777 4.869
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.16
Total Liabilities 12.125 12.293 13.381 12.535 7.896
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1.373 2.601 1.232 2.31 0.869
Total Equity 56.115 97.162 72.148 71.111 110.336
Redeemable Preferred Stock 0 0
Common Stock 0.005 0.005 0.003 0.003 0.003
Additional Paid-In Capital 364.361 361.669 295.281 288.224 280.84
Retained Earnings (Accumulated Deficit) -307.688 -266.381 -223.14 -217.145 -170.473
Other Equity, Total -0.563 1.869 0.004 0.029 -0.034
Total Liabilities & Shareholders’ Equity 68.24 109.455 85.529 83.646 118.232
Total Common Shares Outstanding 46.5535 46.5535 28.3726 27.9532 29.3239
Long Term Investments 21.877 34.266 37.225
Accounts Receivable - Trade, Net 0.588 0.507
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 35.551 43.664 51.272 58.885 64.367
Cash and Short Term Investments 34.467 42.303 49.617 56.723 62.944
Cash & Equivalents 9.654 13.159 24.588 28.477 31.46
Short Term Investments 24.813 29.144 25.029 28.246 31.484
Total Receivables, Net 0.467 0.633 0.534 0.429 0.445
Prepaid Expenses 0.486 0.626 0.724 1.338 0.848
Other Current Assets, Total 0.131 0.102 0.397 0.395 0.13
Total Assets 58.197 68.24 80.348 92.541 101.29
Property/Plant/Equipment, Total - Net 2.283 2.57 2.914 3.239 3.316
Property/Plant/Equipment, Total - Gross 6.886 7.116 7.44 7.67 7.655
Accumulated Depreciation, Total -4.603 -4.546 -4.526 -4.431 -4.339
Long Term Investments 20.234 21.877 25.914 30.181 33.371
Other Long Term Assets, Total 0.129 0.129 0.248 0.236 0.236
Total Current Liabilities 8.29 10.752 13.978 10.156 9.265
Accounts Payable 1.407 1.976 4.227 2.65 2.189
Accrued Expenses 6.883 8.776 9.751 7.506 7.076
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 9.33 12.125 15.667 12.155 11.568
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1.04 1.373 1.689 1.999 2.303
Total Equity 48.867 56.115 64.681 80.386 89.722
Common Stock 0.005 0.005 0.005 0.005 0.005
Additional Paid-In Capital 364.857 364.361 363.741 363.083 362.408
Retained Earnings (Accumulated Deficit) -315.561 -307.688 -297.872 -283.041 -274.678
Other Equity, Total -0.434 -0.563 -1.193 0.339 1.987
Total Liabilities & Shareholders’ Equity 58.197 68.24 80.348 92.541 101.29
Total Common Shares Outstanding 46.5685 46.5535 46.5535 46.5535 46.5535
Accounts Receivable - Trade, Net 0.429 0.588 0.503 0.373 0.373
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -41.307 -43.241 -5.995 -46.672 -46.939
Cash From Operating Activities -27.023 -36.715 -34.778 -37.321 -40.988
Cash From Operating Activities 0.367 0.46 0.632 0.743 0.847
Non-Cash Items 12.505 9.302 -31.324 6.704 6.527
Changes in Working Capital 1.412 -3.236 1.909 1.904 -1.423
Cash From Investing Activities -23.276 21.56 44.769 3.255 -30.192
Capital Expenditures -0.269 -0.005 -0.076 -0.025 -0.355
Other Investing Cash Flow Items, Total -23.007 21.565 44.845 3.28 -29.837
Cash From Financing Activities 0 62.158 1.31 0.024 65.27
Financing Cash Flow Items
Issuance (Retirement) of Stock, Net 0 62.158 1.31 0.024 65.27
Net Change in Cash -50.299 47.003 11.301 -34.042 -5.91
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -7.873 -41.307 -31.491 -16.66 -8.297
Cash From Operating Activities -8.111 -27.023 -19.476 -12.547 -6.424
Cash From Operating Activities 0.057 0.367 0.273 0.179 0.087
Non-Cash Items 1.959 12.505 7.451 4.146 1.835
Changes in Working Capital -2.254 1.412 4.291 -0.212 -0.049
Cash From Investing Activities 4.602 -23.276 -19.394 -22.434 -25.574
Other Investing Cash Flow Items, Total 4.636 -23.007 -19.125 -22.43 -25.574
Cash From Financing Activities 0.004 0 0 0
Issuance (Retirement) of Stock, Net 0.004 0 0 0
Net Change in Cash -3.505 -50.299 -38.87 -34.981 -31.998
Capital Expenditures -0.034 -0.269 -0.269 -0.004

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Corvus Pharmaceuticals, Inc. Company profile

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Corvus Pharmaceuticals Inc revenues was not reported. Net loss increased from $6M to $43.2M. Higher net loss reflects Gain on deconsolidation of Angel Pharmac decrease from $37.5M (income) to $0K, Loss from equity method investment increase from $234K to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.20 to -$1.03.

Industry: Biotechnology & Medical Research (NEC)

863 Mitten Rd Ste 102
BURLINGAME
CALIFORNIA 94010-1311
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

ETH/USD

1,688.52 Price
+0.330% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

BTC/USD

27,198.90 Price
+0.310% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

US100

14,744.20 Price
+0.120% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 7.0

Oil - Crude

90.04 Price
-1.230% 1D Chg, %
Long position overnight fee 0.0661%
Short position overnight fee -0.0881%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading